Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 15, 2023

# Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (Under Japanese GAAP)

Company name: DKS Co. Ltd.

Listing: Tokyo Stock Exchange

Security code: 4461

URL: https://www.dks-web.co.jp
Representative: YAMAJI Naoki, President COO
Inquiries: SHIMIZU Shinji, Director

TEL: +81-75-323-5955

Scheduled date of ordinary general meeting of shareholders: June 23, 2023
Scheduled date to commence dividend payments: June 26, 2023
Scheduled date to file annual securities report: June 23, 2023

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing:

Yes (for institutional investors and

analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

## 1. Consolidated financial results for the fiscal year ended March 31, 2023 (from April 1, 2022 to March 31, 2023)

#### (1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended March 31, 2023	65,081	3.8	1,186	(74.4)	1,200	(71.4)	(407)	-
Fiscal year ended March 31, 2022	62,672	6.0	4,626	3.1	4,192	(2.8)	2,492	(2.8)

Note: Comprehensive income Fiscal year ended March 31, 2023 ¥3,75 million [(89.8)%] Fiscal year ended March 31, 2022 ¥3,697 million [(4.3)%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating income to net sales
Fiscal year ended	Yen	Yen	%	%	%
Fiscal year ended March 31, 2023	(41.87)	_	(1.1)	1.4	1.8
March 31, 2022	244.81	_	7.0	4.9	7.4

Reference: Share of profit (loss) of entities accounted for using equity method

Fiscal year ended March 31, 2023 ¥36 million Fiscal year ended March 31, 2022 ¥55 million

### (2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share	
As of	Millions of yen	Millions of yen	%	Yen	
As of March 31, 2023	85,025	38,296	40.4	3,593.49	
As of March 31, 2022	86,469	40,383	42.5	3,610.31	

Reference: Equity

As of March 31, 2023 ¥34,346 million As of March 31, 2022 ¥36,767 million

### (3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended March 31, 2023	724	(2,883)	(1,030)	9,051
Fiscal year ended March 31, 2022	5,520	(2,700)	(2,336)	12,151

#### 2. Cash dividends

		Annual	dividends p	Total cash		Ratio of		
	First quarter- end	Second quarter- end	Third quarter-end	Fiscal year-end	Total	dividends (Total)	Payout ratio (Consolidated)	dividends to net assets (Consolidated)
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2022	-	35.00	-	45.00	80.00	814	32.7	2.3
Fiscal year ended March 31, 2023	-	40.00	_	40.00	80.00	764	_	2.2
Fiscal year ending March 31, 2024 (Forecast)	_	20.00	-	30.00	50.00		39.8	

## 3. Consolidated earnings forecasts for the fiscal year ending March 31, 2024 (from April 1, 2023 to March 31, 2024)

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Half year	30,000	(8.4)	400	(44.2)	300	(65.6)	100	_	10.46
Full year	68,000	4.5	2,500	110.8	2,300	91.7	1,200	-	125.55

### \* Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

Newly included: - companies Excluded: - companies

- (2) Changes in accounting policies, changes in accounting estimates, and restatement
  - (i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
  - (ii) Changes in accounting policies due to reasons other than (i): None
  - (iii) Changes in accounting estimates: None
  - (iv) Restatement: None

Note: For details, kindly refer to "3. Consolidated Financial Statements and Notes, (5) Notes to consolidated financial statements (Changes in accounting policies)" in page 13 of attached materials.

### (3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2023	10,684,321 shares
As of March 31, 2022	10,684,321 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2023	1,126,227 shares
As of March 31, 2022	500,351 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2023	9,737,450 shares
Fiscal year ended March 31, 2022	10,181,694 shares

### [Reference] Overview of non-consolidated financial results

## Non-consolidated financial results for the fiscal year ended March 31, 2023 (from April 1, 2022 to March 31, 2023)

### (1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended March 31, 2023	43,506	5.0	(826)	_	23	(99.0)	(1,177)	_
Fiscal year ended March 31, 2022	41,452	(3.7)	1,967	(15.9)	2,298	(11.9)	1,750	(20.1)

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
Fiscal year ended March 31, 2023	(120.93)	-
Fiscal year ended March 31, 2022	171.92	-

### (2) Non-consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share	
As of	Millions of yen	Millions of yen	%	Yen	
As of March 31, 2023	63,091	25,368	40.2	2,654.13	
As of March 31, 2022	66,340	28,520	43.0	2,800.53	

Reference: Equity

As of March 31, 2023 \\ \pm 25,368 \text{ million} \\
As of March 31, 2022 \\ \pm 28,520 \text{ million} \\

\* Proper use of earnings forecasts, and other special matters

Forward-looking statements, including the consolidated forecasts stated in these materials, are based on information currently available to the Company and certain assumptions deemed reasonable. Consequently, no statements herein constitute assurances regarding actual results by the Company. Results may differ materially from the consolidated forecasts due to various factors.

<sup>\*</sup> Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

### **Attached Material**

### **Index**

Ι.	Overview of Operating Results, etc.	2
	(1) Overview of Operating Results for the Fiscal Year Under Review	2
	(2) Overview of Financial Position for the Fiscal Year Under Review	4
	(3) Overview of Cash Flows for the Fiscal Year Under Review	4
	(4) Future Outlook	5
	(5) Basic Policy for Profit Distributions and Dividends for Current and Next Fiscal Years	5
2.	Basic Concept Regarding Selection of Accounting Standards	6
3.	Consolidated Financial Statements and Notes	7
	(1) Consolidated Balance Sheet	7
	(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income	9
	(Consolidated statement of income)	
	(Consolidated statement of comprehensive income)	10
	(3) Consolidated statement of changes in equity	11
	(4) Consolidated Statement of Cash Flows	13
	(5) Notes to Consolidated Financial Statements	15
	(Notes on premise of going concern)	15
	(Notes on significant accounting estimate)	
	(Changes in accounting policies)	
	(Notes on Consolidated statement of income)	
	(Segment information, etc.) (Per share information)	
	(Significant events after reporting period)	
	(515mileant 6 vents after reporting period)	2 1

### 1. Overview of Operating Results, etc.

#### (1) Overview of Operating Results for the Fiscal Year Under Review

During the fiscal year under review, the Japanese economy showed signs of a gentle recovery as restrictions on movement to combat COVID-19 eased. On the other hand, the semiconductor shortage, supply chain disruptions limiting the supply of raw materials, and soaring raw material prices due to the protracted situation in Ukraine hampered corporate growth. As such, the outlook remains uncertain.

Under these circumstances, the Group recorded higher sales but lower profits year on year. The aforementioned external factors along with delays in price pass-on and new product development resulted in a major breakdown of the assumptions in place during the establishment of medium-term management plan, "FELIZ 115." The environment surrounding the Company in the fiscal year ending March 31, 2024, the fourth year of the plan, will be difficult, so we do not expect a quick recovery.

First, we will work to improve profitability and secure profits by steadily implementing price pass-on and reducing costs. We will also accelerate product development, increase production of competitive products, and improve our plant operating rates. In the Life Sciences business, we aim to quickly return to profitability through sales promotion and business expansion as the notification for food with functional claims is complete for products containing I. Japonica-Bombyx Fungus.

Concerning the results for the fiscal year ended March 31, 2023, net sales were ¥65,081 million (up 3.8% year on year), thanks to significant sales growth of flame retardants for overseas markets in the Functional Materials segment.

Operating income was ¥1,186 million (down 74.4% year on year). Profit decreased mainly in the Surfactants and Functional Materials segments due primarily to an increase in R&D expenses for the future and a sharp rise in raw material prices that exceeded price pass-on measures. In addition, ordinary income was ¥1,200 million (down 71.4% year on year), despite recovery of non-operating income and expenses. On top of this, an impairment loss was recorded for non-current assets in the Polyurethane Materials segment as an extraordinary loss, so the loss attributable to owners of parent after deducting income tax expenses came to ¥407 million (profit of ¥2,492 million in the previous fiscal year).

Results by segment are as follows.

### Surfactants

Net sales in the Surfactants segment were generally firm.

In Japan, sales were sluggish in IT and electronics applications, and paint and coloring agent applications, but remained firm in machinery and metal applications. Sales for soap and detergent applications grew significantly.

Overseas, sales for rubber and plastic applications were sluggish, but sales remained firm in textile applications.

As a result, net sales in this segment were \\$18,976 million (up 2.2\% year on year).

Operating income was ¥1,749 million (down 29.4% year on year) due to the impact of soaring raw materials prices.

### **Amenity Materials**

Net sales in the Amenity Materials segment were generally sluggish.

In Japan, sales of sucrose fatty acid esters remained firm for food applications, and sales of vinyl polymers were also firm for rubber and plastic applications. Sales of cellulose polymers were sluggish in energy and environmental applications.

Overseas, sales of sucrose fatty acid esters were robust in food applications and personal care (cosmetics) applications.

As a result, net sales in this segment were \(\frac{1}{2}\)8,079 million (down 0.2% year on year).

There was an operating loss of ¥1 million (operating income of ¥566 million in the previous fiscal year) due to the impact of soaring raw material prices and increased operating expenses.

### Polyurethane Materials

Net sales in the Polyurethane Materials segment were generally firm.

Sales of civil engineering chemicals related to public works were strong, and sales of environmentally friendly synthetic lubricants related to CFC regulations grew significantly.

Sales of functional polyurethanes were sluggish in construction and other applications, but sales in IT and electronics applications were firm.

As a result, net sales in this segment were \\$8,761 million (up 5.6% year on year).

The Company posted an operating loss of ¥247 million (operating income of ¥55 million in the previous fiscal year) due to the impact of soaring raw materials prices.

#### **Functional Materials**

Net sales in the Functional Materials segment generally increased significantly.

In Japan, sales of waterborne polyurethane for IT and electronics applications dropped sharply, but sales of radcure resin materials for IT and electronics applications grew significantly. Sales of flame retardants for rubber and plastic applications also grew significantly.

Overseas, sales of flame retardants for rubber and plastics grew significantly, as did sales of radcure resin materials for IT and electronics applications.

As a result, net sales in this segment were \(\frac{\text{\frac{4}}}{22,574}\) million (up 13.3% year on year).

Operating income was ¥281 million (down 79.2% year on year) due to an increase in operating expenses, mainly R&D expenses, in addition to the impact of soaring raw material prices.

### **Electronic Device Materials**

Net sales in the Electronic Device Materials segment fell significantly overall.

Sales of ionic liquids for display applications and conductive pastes for solar cell applications fell significantly.

As a result, net sales in this segment were \(\frac{1}{2}6,191\) million (down 15.4% year on year).

Due to the significant drop in net sales, operating income was \\$139\text{ million (down 80.6\% year on year).}

### Life Sciences

Net sales in the Life Sciences segment increased by ¥20 million (4.4%) year on year, to ¥497 million. Improvement of cognitive function has been confirmed for intake of I. Japonica-Bombyx Fungus containing "Naturido" in clinical trials targeting healthy adults and persons with mild cognitive impairment. In February 2023, notification to the Consumer Affairs Agency for food with functional claims is complete for "Kainou Tochukaso (original Japanese name)" and we plan to launch the product around the summer.

The OEM business for pharmaceutical additives and health foods made through the concentration and pulverization of extracts from natural materials was firm.

As for operating income, although net sales increased, there was an operating loss of ¥734 million (operating loss of ¥543 million in the previous fiscal year) due to an increase in operating expenses, mainly R&D expenses.

#### (2) Overview of Financial Position for the Fiscal Year Under Review

#### (Assets)

Current assets at the end of the fiscal year ended March 31, 2023 were \$45,411 million, down \$1,122 million from the end of the previous fiscal year. This was primarily due to a decrease of \$3,095 million in cash and deposits, despite an increase of \$685 million in electronically recorded monetary claims - operating and an increase of \$1,128 million in inventories such as merchandise and finished goods. Non-current assets totaled \$39,614 million, down \$321 million from the end of the previous fiscal year. This was primarily due to a decrease of \$615 million in property, plant and equipment.

As a result, total assets amounted to \(\frac{4}{8}\)5,025 million, down \(\frac{4}{1}\),443 million from the end of the previous fiscal year.

### (Liabilities)

Current liabilities at the end of the fiscal year ended March 31, 2023 were \(\frac{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{

As a result, total liabilities at the end of the period under review were \(\frac{\pma}{4}\)6,729 million, up \(\frac{\pma}{6}\)643 million from the end of the previous fiscal year.

### (Net assets)

Total net assets at the end of the fiscal year ended March 31, 2023 were \(\frac{\pmax}{2}\)8,296 million, down \(\frac{\pmax}{2}\),087 million from the end of the previous fiscal year. This was primarily due to an increase in treasury shares of \(\frac{\pmax}{1}\),466 million due to purchase of treasury shares and a decrease in retained earnings of \(\frac{\pmax}{1}\),248 million resulting from loss attributable to owners of parent of \(\frac{\pmax}{4}\)407 million and dividend of surplus of \(\frac{\pmax}{8}\)40 million, despite an increase in non-controlling interests of \(\frac{\pmax}{3}\)33 million.

As a result, the equity ratio came to 40.4% (42.5% as of the end of the previous fiscal year).

### (3) Overview of Cash Flows for the Fiscal Year Under Review

Cash and cash equivalents ("cash") at the fiscal year ended March 31, 2023 were \(\frac{1}{2}\)9,051 million, a decrease of \(\frac{1}{2}\)3,099 million compared to the end of the previous fiscal year.

The respective cash flow positions and the factors thereof in the fiscal year ended March 31, 2023 are as follows.

### (Cash flows from operating activities)

Net cash provided by operating activities was ¥724 million (¥5,520 million was provided in the previous fiscal year). This was due to a decrease in funds resulting primarily from an increase in inventories of ¥1,362 million (an increase of ¥2,016 million in the previous fiscal year) and an increase in trade receivables of ¥722 million (a decrease of ¥519 million in the previous fiscal year), and an increase in funds resulting primarily from depreciation of ¥3,295 million (¥3,430 million in the previous fiscal year).

### (Cash flows from investing activities)

Net cash used in investing activities was \$2,883 million (\$2,700 million was used in the previous fiscal year). This was due to a decrease in funds due to expenditures from purchase of property, plant and equipment of \$2,834 million (\$2,661 million for the previous fiscal year).

### (Cash flows from financing activities)

Net cash used in financing activities was \$1,030 million (\$2,336 million was used in the previous fiscal year). This was due to a decrease in funds resulting primarily from repayment of long-term borrowings of \$5,879 million (\$6,595 million in the previous fiscal year), purchase of treasury shares of \$1,500 million, and payment of dividends of \$840 million (\$712 million in the previous fiscal year) despite an increase in funds from proceeds from long-term borrowings of \$7,700 million (\$4,890 million in the previous fiscal year).

### (4) Future Outlook

The Group has entered the fourth year of its medium-term management plan, "FELIZ 115." Initially, we were going to focus on business expansion starting in the third year of the plan, but market stagnation due to the prolonged COVID-19 pandemic, geopolitical risks such as Russia's military invasion of Ukraine, and soaring prices of crude oil, naphtha, and other raw materials have hindered our efforts to secure profits.

In response to this situation, we will come together as a group to work on improving profitability, accelerating our efforts to address urgent management issues such as strengthening segment management, reviewing unprofitable businesses, redistributing management resources, and rebuilding our performance evaluation and compensation system.

For the next fiscal year, we forecast net sales of \$68,000 million, operating income of \$2,500 million, ordinary income of \$2,300 million, profit attributable to owners of parent of \$1,200 million.

### (5) Basic Policy for Profit Distributions and Dividends for Current and Next Fiscal Years

Our basic policy is to maintain long-term and stable dividends to our shareholders while keeping a reasonable level of internal reserves that we deem is necessary for future business development. With regard to internal reserves, we will strive to increase corporate value by actively utilizing these for the investment necessary for future business development that will lead to strengthening international competitiveness and new growth.

Although the business circumstances have been difficult, we will pay a year-end dividend of ¥40 to maintain stable dividends to our shareholders.

Furthermore, in the next fiscal year, because we do not expect a quick recovery from the continuing poor market conditions, we are planning to pay an interim dividend of \(\frac{4}{20}\) per share and a year-end dividend of \(\frac{4}{30}\) per share, for a total annual dividend of \(\frac{4}{50}\) per share. We will accelerate our efforts to address urgent management issues as we work to improve profitability and secure profits.

### 2. Basic Concept Regarding Selection of Accounting Standards

Most of the stakeholders of the Group are domestic shareholders, creditors, business partners, etc., and there is little need to raise funds from overseas, we have applied Japanese standards as accounting standards.

In the future, we plan to consider the application of international accounting standards based on changes in the ratio of foreign shareholders and trends in the application of international accounting standards of other companies in the same industry in Japan.

### 3. Consolidated Financial Statements and Notes

### (1) Consolidated Balance Sheet

		(Millions of y
	As of March 31, 2022	As of March 31, 2023
Assets		
Current assets		
Cash and deposits	12,224	9,128
Notes receivable - trade	526	345
Accounts receivable - trade	14,432	14,759
Electronically recorded monetary claims -	1,532	2,218
operating	1,332	2,210
Merchandise and finished goods	11,582	13,131
Work in process	21	16
Raw materials and supplies	3,905	3,489
Prepaid expenses	317	369
Other	1,996	1,956
Allowance for doubtful accounts	(4)	(3)
Total current assets	46,534	45,411
Non-current assets		
Property, plant and equipment		
Buildings and structures	30,486	30,640
Accumulated depreciation	(16,944)	(17,805)
Buildings and structures, net	13,541	12,834
Machinery, equipment and vehicles	37,426	35,272
Accumulated depreciation	(31,870)	(30,621
Machinery, equipment and vehicles, net	5,555	4,650
Tools, furniture and fixtures	4,144	4,285
Accumulated depreciation	(3,413)	(3,484
Tools, furniture and fixtures, net	730	800
Land	9,638	9,748
Leased assets	4,804	4,582
Accumulated depreciation	(2,004)	(2,244
Leased assets, net	2,800	2,338
Construction in progress	1,091	2,369
Total property, plant and equipment	33,358	32,743
Intangible assets	33,330	32,713
Goodwill	213	
Other	405	341
Total intangible assets	618	341
Investments and other assets	018	541
Investments and other assets  Investment securities	4.004	4 274
Long-term loans receivable	4,004	4,274 14
<u> </u>		
Long-term prepaid expenses Deferred tax assets	231 172	512 299
Retirement benefit asset		
	1,228	1,063
Other Allowance for doubtful accounts	310	371
· · · · · · · · · · · · · · · · · · ·	(6)	(6)
Total investments and other assets	5,958	6,529
		39,614
Total non-current assets Total assets	39,935 86,469	39,61 85,02

	A 4'1:		C	`
- (	V/111	lions	of v	zen i

	As of March 31, 2022	As of March 31, 2023
Liabilities		
Current liabilities		
Notes and accounts payable - trade	10,204	9,972
Electronically recorded obligations - operating	429	379
Short-term borrowings	6,711	6,516
Lease liabilities	558	474
Accrued expenses	348	308
Income taxes payable	576	232
Accrued business office taxes	41	41
Provision for bonuses	816	712
Other	2,040	2,002
Total current liabilities	21,726	20,639
Non-current liabilities		
Corporate bonds	6,000	6,000
Long-term borrowings	15,051	17,348
Lease liabilities	2,551	2,131
Deferred tax liabilities	318	196
Retirement benefit liability	107	79
Asset retirement obligations	74	74
Other	255	259
Total non-current liabilities	24,359	26,089
Total liabilities	46,086	46,729
Vet assets		
Shareholders' equity		
Capital stock	8,895	8,895
Capital surplus	7,278	7,276
Retained earnings	20,498	19,250
Treasury shares	(1,021)	(2,488)
Total shareholders' equity	35,650	32,933
Accumulated other comprehensive income		
Valuation difference on available-for-sale	404	
securities	181	467
Foreign currency translation adjustment	507	765
Remeasurements of defined benefit plans	427	180
Total accumulated other comprehensive income	1,116	1,413
Non-controlling interests	3,616	3,949
Total net assets	40,383	38,296
Total liabilities and net assets	86,469	85,025

## (2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income (Consolidated statement of income)

(Millions of yen) Fiscal year ended March 31, Fiscal year ended March 31, 2022 Net sales 62,672 65,081 Cost of sales 46,954 52,120 12,960 Gross profit 15,718 Selling, general and administrative expenses 4,198 4,173 Selling expenses General and administrative expenses 6,918 7,574 Total selling, general and administrative expenses 11,092 11,773 Operating income 4,626 1,186 Non-operating income Interest income 7 10 85 105 Dividend income Share of profit of entities accounted for using equity 55 36 Foreign exchange gains 55 144 Rental income 35 35 79 89 Other Total non-operating income 319 421 Non-operating expenses 188 199 Interest expenses Corporate bond interest 37 37 365 Inactive facility expenses 162 170 Other Total non-operating expenses 753 407 Ordinary income 4,192 1,200 Extraordinary income Gain on sale of investment securities 50 194 Reversal for provision for waste disposal costs Total extraordinary income 194 50 Extraordinary losses Impairment losses 786 Amortization of goodwill 137 173 102 Loss on disposal of non-current assets Loss on valuation of investment securities 34 Total extraordinary losses 207 1,027 Profit before income taxes 4,179 224 459 Income taxes - current 1,087 (185)Income taxes - deferred 52 Total income taxes 1,139 274 3,039 (49)Profit (loss) 546 357 Profit attributable to non-controlling interests Profit (loss) attributable to owners of parent 2,492 (407)

### (Consolidated statement of comprehensive income)

(Millions of yen) Fiscal year ended March 31, Fiscal year ended March 31, 2022 2023 Profit (loss) 3,039 (49) Other comprehensive income 286 Valuation difference on available-for-sale securities (303)Foreign currency translation adjustment 768 356 Remeasurements of defined benefit plans net of tax 142 (238)Share of other comprehensive income of entities 50 21 accounted for using equity method 658 425 Total other comprehensive income Comprehensive income 3,697 375 Comprehensive income attributable to Comprehensive income attributable to owners of 2,824 (110)parent Comprehensive income attributable to non-872 486 controlling interests

### (3) Consolidated statement of changes in equity

Fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022)

		Shareholders' equity						
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity			
Balance at beginning of period	8,895	7,267	18,733	(1,040)	33,856			
Cumulative effects of changes in accounting policies			(15)		(15)			
Restated balance	8,895	7,267	18,718	(1,040)	33,841			
Changes during period								
Dividends of surplus			(712)		(712)			
Profit (loss) attributable to owners of parent			2,492		2,492			
Purchase of treasury shares				(0)	(0)			
Disposal of treasury shares		11		18	29			
Net changes in items other than shareholders' equity								
Total changes during period	-	11	1,780	18	1,809			
Balance at end of period	8,895	7,278	20,498	(1,021)	35,650			

		Accumulated other co				
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	Non-controlling interests	Total net assets
Balance at beginning of period	484	24	282	791	2,756	37,404
Cumulative effects of changes in accounting policies						(15)
Restated balance	484	24	282	791	2,756	37,389
Changes during period						
Dividends of surplus						(712)
Profit (loss) attributable to owners of parent						2,492
Purchase of treasury shares						(0)
Disposal of treasury shares						29
Net changes in items other than shareholders' equity	(303)	482	145	324	860	1,184
Total changes during period	(303)	482	145	324	860	2,994
Balance at end of period	181	507	427	1,116	3,616	40,383

### Fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023)

		Shareholders' equity					
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity		
Balance at beginning of period	8,895	7,278	20,498	(1,021)	35,650		
Cumulative effects of changes in accounting policies					-		
Restated balance	8,895	7,278	20,498	(1,021)	35,650		
Changes during period							
Dividends of surplus			(840)		(840)		
Profit (loss) attributable to owners of parent			(407)		(407)		
Purchase of treasury shares				(1,500)	(1,500)		
Disposal of treasury shares		(2)		33	31		
Net changes in items other than shareholders' equity							
Total changes during period	_	(2)	(1,248)	(1,466)	(2,717)		
Balance at end of period	8,895	7,276	19,250	(2,488)	32,933		

		Accumulated other co	omprehensive income	e		
	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	Non-controlling interests	Total net assets
Balance at beginning of period	181	507	427	1,116	3,616	40,383
Cumulative effects of changes in accounting policies						-
Restated balance	181	507	427	1,116	3,616	40,383
Changes during period						
Dividends of surplus						(840)
Profit (loss) attributable to owners of parent						(407)
Purchase of treasury shares						(1,500)
Disposal of treasury shares						31
Net changes in items other than shareholders' equity	286	257	(246)	296	333	630
Total changes during period	286	257	(246)	296	333	(2,087)
Balance at end of period	467	765	180	1,413	3,949	38,296

### (4) Consolidated Statement of Cash Flows

		(Millions of y
	Fiscal year ended March 31, 2022	Fiscal year ended March 31 2023
Cash flows from operating activities		
Profit before income taxes	4,179	224
Depreciation	3,430	3,295
Amortization of goodwill	150	213
Increase (decrease) in allowance for doubtful	(9)	(2)
accounts Increase (decrease) in retirement benefit liability	(417)	(249)
Increase (decrease) in provision for waste disposal	(385)	_
costs Interest and dividend income		(115)
	(93) 188	199
Interest expenses		
Corporate bond interest	37	37
Share of loss (profit) of entities accounted for using equity method	(55)	(36)
Impairment losses	-	786
Loss (gain) on disposal of property, plant and equipment	173	102
Loss (gain) on valuation of investment securities	34	_
Loss (gain) on sale of investment securities	_	(50)
Decrease (increase) in trade receivables	519	(722)
Decrease (increase) in inventories	(2,016)	(1,362)
Increase (decrease) in trade payables	744	(321)
Other	213	(442)
Subtotal	6,693	1,556
Interest and dividends received	181	240
Interest paid	(227)	(234)
Income taxes paid	(1,127)	(838)
Net cash provided by (used in) operating activities	5,520	724
Cash flows from investing activities	3,320	/27
Payments into time deposits	(69)	(78)
Proceeds from withdrawal of time deposits	68	78
Purchase of property, plant and equipment	(2,661)	(2,834)
	(2,001)	(2,834)
Proceeds from sale of property, plant and equipment Purchase of investment securities	- (2)	
Proceeds from sale of investment securities	(2)	(2)
Proceeds from collection of loans receivable	_ 1	70
Other		(128)
	(36)	(128)
Net cash provided by (used in) investing activities	(2,700)	(2,883)
Cash flows from financing activities	(52	174
Net increase (decrease) in short-term borrowings	673	174
Proceeds from long-term borrowings	4,890	7,700
Repayments of long-term borrowings	(6,595)	(5,879)
Repayments of lease liabilities	(571)	(531)
Purchase of treasury shares	(0)	(1,500)
Dividends paid	(712)	(840)
Dividends paid to non-controlling interests	(40)	(152)
Proceeds from share issuance to non-controlling shareholders	20	_
Net cash provided by (used in) financing activities	(2,336)	(1,030)
Effect of exchange rate change on cash and cash equivalents	135	89
Net increase (decrease) in cash and cash equivalents	619	(3,099)

		(Millions of yen)
	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Cash and cash equivalents at beginning of period	11,531	12,151
Cash and cash equivalents at end of period	12,151	9,051

### (5) Notes to Consolidated Financial Statements

(Notes on premise of going concern)

Not applicable.

### (Notes on significant accounting estimate)

The following items are recorded in the consolidated financial statements for the fiscal year ended March 31, 2023 based on accounting estimates and may have a significant impact on the consolidated financial statements for the next consolidated fiscal year.

Recoverability of deferred tax assets

### (1) Amount recorded in consolidated financial statements for the fiscal year ended March 31, 2023

(Millions of yen)

	As of March 31, 2022	As of March 31, 2023
Deferred tax assets (before offsetting with deferred tax liabilities)	1,037	1,324

### (2) Information on significant accounting estimates for identified items

At the end of the fiscal year under review, we scheduled the timing of the reversal of deductible temporary differences and tax loss carryforwards based on future taxable income estimated according to future business plans and recorded deferred tax assets to reflect the extent of their effect on reducing the future tax burden.

In this business plan, the main assumptions include progress on price pass-through in response to soaring raw material and energy prices and the sales volume forecast based on projected demand in the product markets to which the Company belongs.

These estimates may be affected by fluctuations in uncertain economic conditions in the future. If the actual timing and amount of taxable income generated differ from the estimates, it could have a material effect on the amount of deferred tax assets in the consolidated financial statements for the next fiscal year.

#### (Changes in accounting policies)

Application of Accounting Standard for Fair Value Measurement, etc.

We have applied the "Implementation Guidance on Accounting Standard for Fair Value Measurement" (ASBJ Guidance No. 31, June 17, 2021; "Fair Value Measurement Implementation Guidance") from the beginning of the fiscal year under review and decided to apply new accounting standards set forth in the Fair Value Measurement Implementation Guidance prospectively in accordance with the transitional treatment provided for in Section 27-2 of the Fair Value Measurement Implementation Guidance.

There is no impact of application of this implementation guidance on the consolidated financial statements.

### (Notes on Consolidated statement of income)

### <u>Inactive facility expenses</u>

Expenses related to inactive equipment in the fiscal year ended March 31, 2022 are fixed costs related to the period during which operation of radcure resin materials manufacturing equipment in the Chitose Plant of the Yokkaichi Branch was suspended, etc.

### (Segment information, etc.)

- a. Segment information
  - 1. Description of Reportable Segments

Our reportable segments are subject to regular review by the Board of Directors to determine resource allocation decisions and assess performance for which separate financial information is available from constituent units of the Company.

We have six reportable segments, that is, "Surfactants," "Amenity Materials," "Polyurethane Materials," "Functional Materials," "Electronic Device Materials" and "Life Sciences," depending on the composition and manufacturing method of the product.

"Surfactants" manufactures and sells nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, etc. "Amenity Materials" manufactures and sells sucrose fatty acid esters, cellulose polymers (CMC), vinyl polymer materials, acrylic polymer materials, etc. "Polyurethane Materials" manufactures and sells polyether polyols, urethane prepolymers, urethane systems, etc. "Functional Materials" manufactures and sells radcure resin materials, waterborne polyurethane resins, flame retardants, amide-based lubricants, etc. "Electronic Device Materials" manufactures and sells ionic liquids, conductive pastes for electronic components, pellets for injection molding, etc. "Life Sciences" manufactures and sells health foods (TENCHUKASOU, I. Japonica-Bombyx Fungus, Sudachin, etc.).

2. Explanation of measurements of sales, profit (loss), asset, and other items for each reportable segment

The method of accounting for the reported business segments is in line with the accounting policies adopted to prepare the consolidated financial statements.

Profit for the reportable segment is based on operating income.

3. Disclosure of sales, profit (loss), asset, and other items for each reportable segment Fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022)

	Reportable segments						(1/1111	Amount	
	Surfactants	Amenity Materials	Polyurethane Materials	Functional Materials	Electronic Device Materials	Life Sciences	Total	Reconciling items (Note) 3	recorded in consolidated financial statements (Note) 1
Net sales									
Revenue from contracts with customers	18,564	8,092	8,294	19,928	7,316	476	62,672	_	62,672
Revenues from external customers	18,564	8,092	8,294	19,928	7,316	476	62,672	_	62,672
Transactions with other segments	-	-	-	-	_	_	-	-	-
Total	18,564	8,092	8,294	19,928	7,316	476	62,672	-	62,672
Segment profit (loss)	2,476	566	55	1,355	715	(543)	4,626	-	4,626
Segment assets	18,009	9,187	10,766	26,732	3,427	1,332	69,455	17,014	86,469
Other items									
Depreciation (Note) 2	922	458	743	1,131	72	55	3,383	46	3,430
Amortization of goodwill	-	-	-	-	_	150	150	-	150
Investments in entities accounted for using equity method	301	-	-	393	_	_	694	_	694
Increase in property, plant and equipment and intangible assets	549	366	69	762	96	80	1,925	_	1,925

### Fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023)

(Millions of yen)

			Rej	portable segme	ents				Amount
	Surfactants	Amenity Materials	Polyurethane Materials	Functional Materials	Electronic Device Materials	Life Sciences	Total	Reconciling items (Note) 3	recorded in consolidated financial statements (Note) 1
Net sales									
Revenue from contracts with customers	18,976	8,079	8,761	22,574	6,191	497	65,081	-	65,081
Revenues from external customers	18,976	8,079	8,761	22,574	6,191	497	65,081	_	65,081
Transactions with other segments	_	-	_	-	_	_	_	-	_
Total	18,976	8,079	8,761	22,574	6,191	497	65,081	-	65,081
Segment profit (loss)	1,749	(1)	(247)	281	139	(734)	1,186	-	1,186
Segment assets	18,120	9,361	9,284	28,732	3,288	1,133	69,920	15,104	85,025
Other items									
Depreciation (Note) 2	748	500	534	1,324	86	57	3,250	44	3,295
Amortization of goodwill	-	-	-	-	-	213	213	-	213
Investments in entities accounted for using equity method	301	_	_	339	_	_	640	_	640
Increase in property, plant and equipment and intangible assets	1,012	604	28	1,357	151	18	3,172	_	3,172

Notes: 1. Total amount of profit or loss in reportable segments and operating income in the consolidated statement of income coincide.

- 2. Depreciation includes depreciation expenses associated with long-term prepaid expenses.
- 3. The adjustment amount is surplus assets under management (cash and deposits), long-term investment funds (investment securities) and assets related to the administrative department at the filing company.

### b. Information associated with reportable segments

Fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022)

### 1. Information for Each Product or Service

(Millions of yen)

	Surfactants	Amenity Materials	Polyurethane Materials	Functional Materials	Electronic Device Materials	Life Sciences	Total
Revenues from external customers	18,564	8,092	8,294	19,928	7,316	476	62,672

### 2. Information for Each Region

### (1) Net sales

(Millions of yen)

Japan	Asia	Other	Total
48,596	12,512	1,563	62,672

Notes: 1. Net sales is classified by country or region based on customers' location.

- 2. Countries and regions are segmented by geographical proximity.
- 3. Major countries or regions included in each category:
  - (i) Asia Taiwan, China, South Korea, Indonesia
  - (ii) Other regions North America, Europe

### (2) Property, plant and equipment

(Millions of yen)

Japan	Taiwan	Other	Total
27,668	5,545	144	33,358

Notes:

- 1. Property, plant and equipment is classified by country or region based on companies' location.
- 2. Major countries or regions included in "Other": China, Indonesia, Netherlands

Fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023)

### 1. Information for Each Product or Service

	Surfactants	Amenity Materials	Polyurethane Materials	Functional Materials	Electronic Device Materials	Life Sciences	Total
Revenues from external customers	18,976	8,079	8,761	22,574	6,191	497	65,081

### 2. Information for Each Region

#### (1) Net sales

(Millions of yen)

Japan	Asia	Other	Total
49,574	13,578	1,927	65,081

Notes:

- 1. Net sales is classified by country or region based on customers' location.
- 2. Countries and regions are segmented by geographical proximity.
- 3. Major countries or regions included in each category:
  - (i) Asia Taiwan, China, South Korea, Indonesia
  - (ii) Other regions North America, Europe

### (2) Property, plant and equipment

(Millions of yen)

Japan	Taiwan	Other	Total
26,548	5,964	229	32,743

Notes:

- 1. Property, plant and equipment is classified by country or region based on companies' location.
- Major countries or regions included in "Other": China, Indonesia, Netherlands
- c. Disclosure of impairment losses on non-current assets for each reportable segment
  Fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022)
  Not applicable.

Fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023)

(Millions of yen)

	Surfactants		Polyurethan e Materials		Electronic Device Materials	Life Sciences	Unallocated amounts and elimination	
Impairment losses	-	I	786	1	l	I	ı	786

(Significant impairment losses related to non-current assets)

In the Polyurethane Materials segment, non-current assets belonging to the Company's asset group in the Polyurethane Materials segment declined due to delays in product price revision activities and new product development activities in response to soaring raw material prices. In conjunction with this, the book value of the assets was reduced to the recoverable amount, and that amount was recorded under extraordinary losses as an impairment loss. The recoverable amount of this asset group is measured by utility value, which is zero because no future cash flows are expected.

d. Amortization and unamortized balance of goodwill for each reportable segment Fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022)

(Millions of yen)

	Surfactants	Amenity Materials	Polyurethan e Materials		Electronic Device Materials	Life Sciences	Unallocated amounts and elimination	
Amortizatio n in the fiscal year	-	-	-	-	-	150	-	150
Balance at end of period	_	-	_	_	_	213	_	213

Fiscal year ended March 31, 2023 (April 1, 2022 to March 31, 2023)

(Millions of yen)

	Surfactants	Amenity Materials	Polyurethan e Materials		Electronic Device Materials	Life Sciences	Unallocated amounts and elimination	
Amortizatio n in the fiscal year	_	_	_	_	_	213	_	213
Balance at end of period	_	-	_	_	_	-	_	_

Note: Amortization in the fiscal year under review in the Life Sciences segment includes amortization in accordance with the provisions of paragraph (32) of the "Practical Guidelines on Accounting Standards for Capital Consolidation Procedures in Preparing Consolidated Financial Statements" (final revision of JICPA Accounting Practice Committee Statement No. 7, October 28, 2022).

### (Per share information)

(Yen)

	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Net assets per share	3,610.31	3,593.49
Basic earnings (loss) per share	244.81	(41.87)

Notes: 1. The amount of diluted earnings per share is not provided because there are no potential shares.

2. The basis for calculation of net assets per share is as follows:

	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Total net assets	40,383	38,296
Deduction from total net assets	3,616	3,949
(Non-controlling interests)	(3,616)	(3,949)
Net assets attributable to ordinary shares at the end of the period	36,767	34,346
Number of ordinary shares at the end of period used for calculating the amounts of net assets per share (Thousands of shares)	10,183	9,558

### 3. The basis for calculation of basic earnings (loss) per share is as follows:

(Millions of yen)

	Fiscal year ended March 31, 2022	Fiscal year ended March 31, 2023
Basic earnings (loss) per share		
Profit (loss) attributable to owners of parent (Millions of yen)	2,492	(407)
Amounts not attributable to ordinary shareholders (Millions of yen)	-	
Profit (loss) attributable to owners of parent for ordinary shares (Millions of yen)	2,492	(407)
Average number of ordinary shares outstanding during the period (Thousands of shares)	10,181	9,737

### (Significant events after reporting period)

Not applicable.